Pirenoxine sodium eye drops

Studies have shown that one of the causes of cataract formation is that soluble proteins in the lens are gradually transformed into insoluble proteins by the action of quinones. Quinones are formed by the abnormal metabolism of tryptophan, an important functional amino acid in the body. The effect of such quinones on soluble proteins in the lens can be competitively inhibited by pyrenoxetine sodium. In addition, pyrenoxetine sodium can also fight against cataracts caused by free radical damage to the lens. Therefore, this product has a certain inhibitory effect on the development of cataracts. Animal experiments have shown that pyrenoxetine sodium can reduce the incidence of posterior capsule opacity after extracapsular cataract extraction.

Main ingredient: Sodium pyrenoxine. Its chemical name is: 1-hydroxy-5-oxo-5H-pyrido-[3,2-alpha;]-phenoxazine-3-carboxylate sodium (monohydrate) Molecular formula: C16H7N2NaO5H2O Molecular weight: 348.25

The tablets of this product are orange-red tablets, and the special solvent is a colorless clear liquid.

It is mainly used to treat early senile cataracts, mild diabetic cataracts or complicated cataracts.

Apply in eyes, 3 to 4 times a day, 1 to 2 drops each time.

Very few patients may experience mild eye pain.

Do not use in case of eye injury or severe infection, or follow doctor's advice.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Not yet clear.

Keep away from light and stored in a sealed place.

15ml:0.8mg

24 months

Anhui Aike'er Pharmaceutical Co., Ltd.

• Founded in:

  2014-06-20

• Address:

  No. 290, Guandian Economic Development Zone, Mingguang City, Anhui Province

• Tax NO.:

  913411823976695617

• Registered Funds:

  10 million yuan

• Email:

  Log in to view